Shenzhen Neptunus Bioengineering Co Ltd (000078) - Net Assets
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has net assets worth CN¥2.85 Billion CNY (≈ $416.32 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥27.28 Billion ≈ $3.99 Billion USD) and total liabilities (CN¥24.43 Billion ≈ $3.58 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000078 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.85 Billion |
| % of Total Assets | 10.43% |
| Annual Growth Rate | 14.78% |
| 5-Year Change | -62.03% |
| 10-Year Change | 32.7% |
| Growth Volatility | 140.26 |
Shenzhen Neptunus Bioengineering Co Ltd - Net Assets Trend (1995–2024)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Shenzhen Neptunus Bioengineering Co Ltd for the complete picture of this company's asset base.
Annual Net Assets for Shenzhen Neptunus Bioengineering Co Ltd (1995–2024)
The table below shows the annual net assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2024. For live valuation and market cap data, see 000078 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.84 Billion ≈ $416.13 Million |
-32.57% |
| 2023-12-31 | CN¥4.22 Billion ≈ $617.14 Million |
-30.98% |
| 2022-12-31 | CN¥6.11 Billion ≈ $894.15 Million |
-16.39% |
| 2021-12-31 | CN¥7.31 Billion ≈ $1.07 Billion |
-2.42% |
| 2020-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
-4.60% |
| 2019-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+9.67% |
| 2018-12-31 | CN¥7.16 Billion ≈ $1.05 Billion |
+10.64% |
| 2017-12-31 | CN¥6.47 Billion ≈ $946.76 Million |
+10.07% |
| 2016-12-31 | CN¥5.88 Billion ≈ $860.13 Million |
+174.28% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.60 Million |
+20.22% |
| 2014-12-31 | CN¥1.78 Billion ≈ $260.85 Million |
-5.58% |
| 2013-12-31 | CN¥1.89 Billion ≈ $276.27 Million |
+78.62% |
| 2012-12-31 | CN¥1.06 Billion ≈ $154.67 Million |
+8.85% |
| 2011-12-31 | CN¥971.04 Million ≈ $142.09 Million |
+7.58% |
| 2010-12-31 | CN¥902.62 Million ≈ $132.08 Million |
+30.33% |
| 2009-12-31 | CN¥692.59 Million ≈ $101.35 Million |
-11.30% |
| 2008-12-31 | CN¥780.79 Million ≈ $114.25 Million |
-13.59% |
| 2007-12-31 | CN¥903.62 Million ≈ $132.23 Million |
+4.01% |
| 2006-12-31 | CN¥868.76 Million ≈ $127.13 Million |
+7.89% |
| 2005-12-31 | CN¥805.26 Million ≈ $117.83 Million |
-44.54% |
| 2004-12-31 | CN¥1.45 Billion ≈ $212.47 Million |
+0.59% |
| 2003-12-31 | CN¥1.44 Billion ≈ $211.22 Million |
-30.04% |
| 2002-12-31 | CN¥2.06 Billion ≈ $301.91 Million |
+4.48% |
| 2001-12-31 | CN¥1.97 Billion ≈ $288.97 Million |
+727.14% |
| 2000-12-31 | CN¥238.75 Million ≈ $34.94 Million |
+16.07% |
| 1999-12-31 | CN¥205.69 Million ≈ $30.10 Million |
+16.16% |
| 1998-12-31 | CN¥177.08 Million ≈ $25.91 Million |
+207.28% |
| 1997-12-31 | CN¥57.63 Million ≈ $8.43 Million |
+2.64% |
| 1996-12-31 | CN¥56.14 Million ≈ $8.22 Million |
+7.65% |
| 1995-12-31 | CN¥52.15 Million ≈ $7.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Neptunus Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 292403177000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥2.63 Billion | 146.56% |
| Other Comprehensive Income | CN¥135.56 Million | 7.55% |
| Other Components | CN¥1.95 Billion | 108.77% |
| Total Equity | CN¥1.80 Billion | 100.00% |
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Market Cap
The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rush Enterprises B Inc
NASDAQ:RUSHB
|
$1.22 Billion |
|
Strait Innovation Internet Co Ltd
SHE:300300
|
$1.22 Billion |
|
Simply Good Foods Co
NASDAQ:SMPL
|
$1.22 Billion |
|
Suzhou Jinfu New Material Co
SHE:300128
|
$1.23 Billion |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
$1.22 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
$1.22 Billion |
|
Power HF Co Ltd
SHG:605100
|
$1.22 Billion |
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
$1.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Neptunus Bioengineering Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,002,922,640 to 1,795,232,448, a change of -1,207,690,192 (-40.2%).
- Net loss of 1,193,414,951 reduced equity.
- Dividend payments of 506,639,806 reduced retained earnings.
- Other comprehensive income increased equity by 410,674,355.
- Other factors increased equity by 81,690,210.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-1.19 Billion | -66.48% |
| Dividends Paid | CN¥506.64 Million | -28.22% |
| Other Comprehensive Income | CN¥410.67 Million | +22.88% |
| Other Changes | CN¥81.69 Million | +4.55% |
| Total Change | CN¥- | -40.22% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Neptunus Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 94.79x to 4.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | CN¥0.03 | CN¥3.18 | x |
| 1996-12-31 | CN¥0.04 | CN¥3.18 | x |
| 1997-12-31 | CN¥0.04 | CN¥3.18 | x |
| 1998-12-31 | CN¥0.11 | CN¥3.18 | x |
| 1999-12-31 | CN¥0.13 | CN¥3.18 | x |
| 2000-12-31 | CN¥0.15 | CN¥3.18 | x |
| 2001-12-31 | CN¥1.08 | CN¥3.18 | x |
| 2002-12-31 | CN¥0.77 | CN¥3.18 | x |
| 2003-12-31 | CN¥0.65 | CN¥3.18 | x |
| 2004-12-31 | CN¥0.64 | CN¥3.18 | x |
| 2005-12-31 | CN¥0.32 | CN¥3.18 | x |
| 2006-12-31 | CN¥0.46 | CN¥3.18 | x |
| 2007-12-31 | CN¥0.46 | CN¥3.18 | x |
| 2008-12-31 | CN¥0.43 | CN¥3.18 | x |
| 2009-12-31 | CN¥0.39 | CN¥3.18 | x |
| 2010-12-31 | CN¥0.45 | CN¥3.18 | x |
| 2011-12-31 | CN¥0.49 | CN¥3.18 | x |
| 2012-12-31 | CN¥0.52 | CN¥3.18 | x |
| 2013-12-31 | CN¥0.86 | CN¥3.18 | x |
| 2014-12-31 | CN¥0.79 | CN¥3.18 | x |
| 2015-12-31 | CN¥0.98 | CN¥3.18 | x |
| 2016-12-31 | CN¥2.41 | CN¥3.18 | x |
| 2017-12-31 | CN¥2.10 | CN¥3.18 | x |
| 2018-12-31 | CN¥2.25 | CN¥3.18 | x |
| 2019-12-31 | CN¥2.36 | CN¥3.18 | x |
| 2020-12-31 | CN¥2.24 | CN¥3.18 | x |
| 2021-12-31 | CN¥2.22 | CN¥3.18 | x |
| 2022-12-31 | CN¥1.78 | CN¥3.18 | x |
| 2023-12-31 | CN¥1.14 | CN¥3.18 | x |
| 2024-12-31 | CN¥0.68 | CN¥3.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Neptunus Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.94%
- • Asset Turnover: 1.05x
- • Equity Multiplier: 16.04x
- Recent ROE (-66.48%) is below the historical average (-0.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 21.94% | 22.82% | 0.60x | 1.59x | CN¥6.19 Million |
| 1996 | 31.19% | 21.85% | 0.63x | 2.26x | CN¥11.55 Million |
| 1997 | 31.69% | 28.97% | 0.43x | 2.54x | CN¥12.43 Million |
| 1998 | 14.83% | 40.56% | 0.28x | 1.30x | CN¥8.52 Million |
| 1999 | 15.17% | 35.15% | 0.14x | 3.14x | CN¥10.59 Million |
| 2000 | 26.11% | 30.92% | 0.23x | 3.70x | CN¥37.96 Million |
| 2001 | 4.79% | 10.43% | 0.25x | 1.83x | CN¥-86.83 Million |
| 2002 | 2.50% | 5.09% | 0.24x | 2.03x | CN¥-126.79 Million |
| 2003 | -15.60% | -17.16% | 0.32x | 2.86x | CN¥-360.99 Million |
| 2004 | 1.58% | 0.95% | 0.62x | 2.67x | CN¥-117.57 Million |
| 2005 | -107.62% | -27.91% | 0.67x | 5.78x | CN¥-810.82 Million |
| 2006 | 5.93% | 1.58% | 0.76x | 4.92x | CN¥-29.16 Million |
| 2007 | 5.17% | 1.55% | 0.80x | 4.17x | CN¥-36.11 Million |
| 2008 | 3.46% | 1.10% | 0.80x | 3.95x | CN¥-46.02 Million |
| 2009 | 2.25% | 0.52% | 0.86x | 5.03x | CN¥-48.79 Million |
| 2010 | 6.29% | 1.17% | 0.96x | 5.59x | CN¥-27.50 Million |
| 2011 | 6.63% | 0.99% | 1.10x | 6.11x | CN¥-26.65 Million |
| 2012 | 7.00% | 0.92% | 1.09x | 6.95x | CN¥-25.27 Million |
| 2013 | 7.69% | 1.46% | 1.00x | 5.27x | CN¥-35.19 Million |
| 2014 | 1.65% | 0.24% | 1.02x | 6.70x | CN¥-120.00 Million |
| 2015 | 26.31% | 4.27% | 0.87x | 7.07x | CN¥294.29 Million |
| 2016 | 7.80% | 3.08% | 0.82x | 3.10x | CN¥-118.21 Million |
| 2017 | 11.53% | 2.55% | 0.81x | 5.59x | CN¥84.66 Million |
| 2018 | 6.93% | 1.08% | 0.93x | 6.87x | CN¥-183.61 Million |
| 2019 | 3.30% | 0.50% | 1.01x | 6.58x | CN¥-419.22 Million |
| 2020 | -4.91% | -0.72% | 1.01x | 6.76x | CN¥-876.41 Million |
| 2021 | 1.60% | 0.23% | 1.09x | 6.46x | CN¥-488.92 Million |
| 2022 | -21.89% | -2.71% | 1.04x | 7.73x | CN¥-1.50 Billion |
| 2023 | -56.28% | -4.64% | 1.13x | 10.76x | CN¥-1.99 Billion |
| 2024 | -66.48% | -3.94% | 1.05x | 16.04x | CN¥-1.37 Billion |
Industry Comparison
This section compares Shenzhen Neptunus Bioengineering Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,180,912,605
- Average return on equity (ROE) among peers: 9.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | CN¥2.85 Billion | 21.94% | 8.59x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more